Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells.

BACKGROUND GnRH-II has been shown to exert a strong antiproliferative action on tumors of the female reproductive system. The data so far reported on the effects of GnRH-II on prostate cancer growth are controversial. Moreover, it is still unclear through which receptor [type I or type II GnRH-receptor (GnRH-R)] GnRH-II might modulate cancer cell proliferation. OBJECTIVE The objective of this work was to investigate whether GnRH-II might affect the proliferation of prostate cancer cells and to identify the GnRH-R through which the peptide might exert its activity. DESIGN We investigated the effects of GnRH-II on prostate cancer cell proliferation. We then transfected PC3 cells with a small interfering RNA targeted to type I GnRH-R. After receptor silencing we evaluated the effects of GnRH-II on cell proliferation and on forskolin-induced intracellular cAMP accumulation. Similar experiments were performed by silencing type II GnRH-R. RESULTS GnRH-II exerted an antiproliferative activity on prostate cancer cells. Transfection of PC3 cells with a type I GnRH-R small interfering RNA resulted in a significant decrease of the expression of this receptor. After type I GnRH-R silencing: 1) the antiproliferative effect of GnRH-II was completely abrogated; and 2) GnRH-II lost its capacity to counteract the forskolin-induced cAMP accumulation. On the contrary, type II GnRH-R silencing did not counteract the antiproliferative effect of GnRH-II. CONCLUSIONS GnRH-II exerts a specific and significant antiproliferative action on prostate cancer cells. This antitumor effect is mediated by the activation of type I (but not of type II) GnRH-R and by its coupled cAMP intracellular signaling pathway.

[1]  Adam J Pawson,et al.  Diversity of actions of GnRHs mediated by ligand-induced selective signaling , 2008, Frontiers in Neuroendocrinology.

[2]  V. Gnanapragasam,et al.  Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. , 2007, Endocrine-related cancer.

[3]  A. Schally,et al.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[4]  P. Limonta,et al.  Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. , 2007, International journal of oncology.

[5]  Adam J Pawson,et al.  Activation of Mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent , 2006, Molecular and Cellular Endocrinology.

[6]  M. Motta,et al.  Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? , 2006, Current cancer drug targets.

[7]  R. Seger,et al.  Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. , 2006, Cancer letters.

[8]  P. Leung,et al.  Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. , 2006, Endocrine-related cancer.

[9]  G. Emons,et al.  Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. , 2005, European journal of endocrinology.

[10]  H. Vaudry,et al.  Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. , 2005, The Journal of clinical endocrinology and metabolism.

[11]  Adam J Pawson,et al.  Inhibition of human type i gonadotropin-releasing hormone receptor (GnRHR) function by expression of a human type II GnRHR gene fragment. , 2005, Endocrinology.

[12]  J. Simard,et al.  Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. , 2005, Endocrine reviews.

[13]  V. Gnanapragasam,et al.  Evidence that prostate gonadotropin‐releasing hormone receptors mediate an anti‐tumourigenic response to analogue therapy in hormone refractory prostate cancer , 2005, The Journal of pathology.

[14]  P. Leung,et al.  Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. , 2005, The Journal of clinical endocrinology and metabolism.

[15]  M. Enomoto,et al.  GnRH as a Cell Proliferation Regulator: Mechanism of Action and Evolutionary Implications , 2004, Zoological science.

[16]  G. Emons,et al.  Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. , 2004, European journal of endocrinology.

[17]  P. Leung,et al.  Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. , 2004, The Journal of clinical endocrinology and metabolism.

[18]  M. Motta,et al.  The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans , 2003, Frontiers in Neuroendocrinology.

[19]  G. Emons,et al.  Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.

[20]  P. Leung,et al.  Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. , 2003, Endocrine-related cancer.

[21]  Adam J Pawson,et al.  A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. , 2003, Endocrinology.

[22]  R. Millar.  GnRH II and type II GnRH receptors , 2003, Trends in Endocrinology & Metabolism.

[23]  S. K. Kang,et al.  International Congress on Hormonal Steroids and Hormones and Cancer Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer , 2003 .

[24]  G. Emons,et al.  Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  J. D. Neill.  Minireview: GnRH and GnRH Receptor Genes in the Human Genome. , 2002, Endocrinology.

[26]  J. D. Neill.  GnRH and GnRH receptor genes in the human genome. , 2002, Endocrinology.

[27]  G. Emons,et al.  Biology of the gonadotropin-releasing hormone system in gynecological cancers. , 2002, European journal of endocrinology.

[28]  Y. Koch,et al.  Transcriptional regulation of the human GnRH II gene is mediated by a putative cAMP response element. , 2001, Endocrinology.

[29]  P. Stattin,et al.  Gonadotropin‐releasing hormone receptor expression in the human prostate , 2001, The Prostate.

[30]  G. Emons,et al.  Antiproliferative Signaling of Luteinizing Hormone-Releasing Hormone in Human Endometrial and Ovarian Cancer Cells through G Proteinα I-Mediated Activation of Phosphotyrosine Phosphatase. , 2001, Endocrinology.

[31]  R. Seger,et al.  Mechanism of GnRH receptor signaling on gonadotropin release and gene expression in pituitary gonadotrophs. , 2001, Vitamins and hormones.

[32]  T. Tamaya,et al.  GnRH receptor and apoptotic signaling. , 2000, Vitamins and hormones.

[33]  M. Motta,et al.  The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. , 1999, Endocrinology.

[34]  D. Polizzi,et al.  Growth‐inhibitory effects of luteinizing hormone‐releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen‐independent prostate cancer cell line in nude mice , 1998, International journal of cancer.

[35]  J. Eisen,et al.  Second gene for gonadotropin-releasing hormone in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Motta,et al.  Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. , 1994, Cancer research.

[37]  A. Schally,et al.  The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. , 1994, Human reproduction.

[38]  A. Schally.  Hypothalamic hormones: from neuroendocrinology to cancer therapy. , 1994, Anti-cancer drugs.

[39]  M. Filicori.  Gonadotrophin-releasing hormone agonists. A guide to use and selection. , 1994, Drugs.

[40]  W. Crowley,et al.  Gonadotropin-releasing hormone and its analogs. , 1994, Annual review of medicine.

[41]  M. Motta,et al.  Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. , 1993, The Journal of clinical endocrinology and metabolism.

[42]  M. Motta,et al.  Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. , 1992, The Journal of clinical endocrinology and metabolism.